Oncologie

, Volume 9, Issue 7–8, pp 517–520

Cancers gynécologiques

Compterendu Actualités de l’ASCO 2007
  • 18 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Alberts DS, Liu PY, Hannigan EV, et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955PubMedCrossRefGoogle Scholar
  2. 2.
    Alberts DS, Liu PY, Wilczynski S, et al. (2007) Phase III randomized trial of pegylated liposomal doxorubicin plus carboplatin versus carboplatin in platinum-sensitive patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: SWOG protocol S0200. ASCO Annual Meeting Proceedings, abstract 5551Google Scholar
  3. 3.
    Armstrong DK, Bundy B, Wenzel L, et al. (2006) Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. GOG 172. N Engl J Med 354(1): 34–43CrossRefGoogle Scholar
  4. 4.
    Bolis G, Scarfone G, Giardina G, et al. (2001) ARGO 96 study group. Carboplatin alone versus carboplatin plus epidoxorubicin as second-line therapy for cisplatin or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81: 3–9PubMedCrossRefGoogle Scholar
  5. 5.
    Conte PF, Favalli G, Gadducci A, et al. (2007) Final results of after-6 protocol 1: a phase III trial of observation versus 6 courses of paclitaxel in advanced ovarian cancer patients in complete response after platinum-paclitaxel chemotherapy. ASCO Annual Meeting Proceedings, abstract 5505Google Scholar
  6. 6.
    Creasman WT, Odicino F, Maisonneuve P, et al. (2003) Carcinoma of the corpus uteri. Int J Gynaecol Obstet 83(Suppl. 1): 79–118PubMedCrossRefGoogle Scholar
  7. 7.
    Creutzberg CL, Van Putten WL, Koper PC, et al. (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage 1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Lancet 355: 1404–1411Google Scholar
  8. 8.
    Ferrandina G, Lorusso D, Pignata S, et al. (2007) A randomized phase III study of gemcitabine versus pegylated liposomal doxorubicin in progressive/recurrent ovarian cancer. ASCO Annual Meeting Proceedings, abstract 5506Google Scholar
  9. 9.
    Gordon AN, Fleagle JT, Guthrie D, et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312–3322PubMedGoogle Scholar
  10. 10.
    Hogberg T, Rosenberg P, Kristensen G, et al. (2007) A randomized phase III study on adjuvant treatment with radiation ± chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). ASCO Annual Meeting Proceedings, abstract 5503Google Scholar
  11. 11.
    Keys HM, Roberts JA, Brunetto VL, et al. (2004) A phase III trial of surgery with or without ajunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A GOG study. Gynecol Oncol 92: 744–751PubMedCrossRefGoogle Scholar
  12. 12.
    Konner JA, Fallon K, Pezzuli S, et al. (2007) A phase II study of intravenous (i.v.) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. ASCO Annual Meeting Proceedings, abstract 5523Google Scholar
  13. 13.
    Krasner CN, Seiden MV, Fuller Jr. AF, et al. (2007) Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. ASCO Annual Meeting Proceedings, abstract 5521Google Scholar
  14. 14.
    Lhommé C, Petit T, Largillier R, et al. (2007) Concomitant weekly carboplatin and paclitaxel with pelvic radiotherapy for the treatment of advanced cercical cancer: a FNCLCC gynecologic group phase I trial. ASCO Annual Meeting Proceedings, abstract 5542Google Scholar
  15. 15.
    Markman M, Bookman MA. (2000) Second-line treatment of ovarian cancer. Oncologist 5: 26–35PubMedCrossRefGoogle Scholar
  16. 16.
    Markman M, Bundy BN, Alberts DS, et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma. An intergroup study of the GOG, SWOG, and ECOG. J Clin Oncol 19: 1001–1007PubMedGoogle Scholar
  17. 17.
    Markman M, Liu PW, Wilczynski S, et al. (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancerafter complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21: 2460–2465PubMedCrossRefGoogle Scholar
  18. 18.
    Markman M, Liu PW, Wilczynski S, et al. (2006) Survival of ovarian cancer patients treated on SWOG 9701/GOG 178: 12 versus 3 cycles of monthly single-agent paclitaxel following attainment of a clinically-defined complete response to platinum. ASCO Annual Meeting Proceedings, abstract 5005Google Scholar
  19. 19.
    Moore DH (2006) Chemotherapy for recurrent cervical carcinoma. Curr Opin Oncol 18: 516–519PubMedCrossRefGoogle Scholar
  20. 20.
    Orton J, on behalf of ASTEC/EN.5 collaborators (2007) Adjuvant external beam radiotherapy in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. ASCO Annual Meeting Proceedings, abstract 5504Google Scholar
  21. 21.
    Parmar MK, Ledermann JA, Colombo N, et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR 2.2 trial. Lancet 361: 2099–2106PubMedCrossRefGoogle Scholar
  22. 22.
    Pautier P, Joly F, Kerbrat P, et al. (2007) Gefitinib in combination with paclitaxel and carboplatin as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: final results of a phase II study. ASCO Annual Meeting Proceedings, abstract 5566Google Scholar
  23. 23.
    Pfisterer J, Plante M, Vergote I, et al. (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC-CTG, and the EORTC-GCG. J Clin Oncol 24: 4699–4707PubMedCrossRefGoogle Scholar
  24. 24.
    Rose PG (2006) Concurrent chemoradiation for locally advanced carcinoma of the cervix: where are we in 2006. Ann Oncol 17(Suppl. 10): 224–229CrossRefGoogle Scholar
  25. 25.
    Sehouli J, Oskay-Oezcelik G, Stengel D, et al. (2007) Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized, two-stage phase II study of the North-Eastern German Society of Gynaecological Oncology. ASCO Annual Meeting Proceedings, abstract 5526Google Scholar
  26. 26.
    Swart AC, on behalf ICON collaborators (2007) Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). ASCO Annual Meeting Proceedings, abstract 5509Google Scholar
  27. 27.
    Trimbos JB, Parmar M, Vergote I, et al. (2003) ICON trial 1 and ACTION trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95: 105–112PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2007

Authors and Affiliations

  1. 1.Département d’oncologie médicaleCLCC Paul-StraussStrasbourg cedexFrance

Personalised recommendations